Alan Spatz
MD, MSc
Dr. Alan Spatz is a Professor of Pathology and Oncology at 麻豆AV, Chief of the Department of Clinical Laboratory Medicine at the 麻豆AV Health Center (MUHC), and Medical Director of Optilab Montreal-MUHC, an integrated network of labs belonging to the 麻豆AV affiliated hospitals. He is also Director of the molecular pathology center and of the 鈥淴 chromosome and cancer鈥� research lab at the Lady David Institute (LDI)/Jewish General Hospital (JGH) of Montreal.
Dr. Spatz received his medical education at the Sorbonne University, Paris, France, and worked at the Gustave Roussy Cancer Institute in Villejuif, France, from 1994 to 2008.
Dr. Spatz serves on the board and steering committee of several international and Canadian research organizations that include the , , and the Canadian BEAT-cancer coalition for advanced molecular diagnostics. He is currently Chair of the Correlative Sciences committee of the Canadian Cancer Trials Group (CCTG) and President of the Cancer Committee of the Quebec Network of Molecular Diagnostic (RQDM). He was the Chair of several clinical research organizations, including the Melanoma group of the European Organization for Research and Treatment of Cancer (EORTC), the Pathobiology group of the EORTC that he founded, the Melanoma committee of the CCTG, and was president of the French division of the International Academy of Pathology.
Dr. Spatz鈥� research is focused on cancer biomarkers and on the role of the X chromosome-related haploinsufficency in cancer progression. He has published more than 230 peer reviewed articles and books in highly ranked journals including Nature Medicine, Nature Cancer, Nature Cancer Reviews, Lancet, Science Translational Medicine, Science Immunology, Annals of Oncology, and Journal of Clinical Oncology.